A study says drug approvals way down.
The study presented at a biotechnology industry conference, BIO CEO & Investor Conference, says that the success rate for getting new drugs approved has fallen by about 50%.
Drug companies have been raising more complaints recently about a regulatory environment that has begun to err on the side of safety when reviewing the risk/benefit trade-offs for new drugs.
Of course, one wonders what the issues is. Isn’t safety supposed to be a key function of the FDA approval process. Perhaps the recent aspat of highly publicized safetly problems with approved drugs is finally registering.
A whole field of alternative medicine, safe and unexplored is open to development by companies, but don’t hold your breath.